SOM Biotech
Baldiri Reixac, 4
Barcelona
08028
Tel: 34-934-020-150
Website: http://sombiotech.com/
Email: info@sombiotech.com
About SOM Biotech
SOM Biotech Ltd. is a med-tech biopharmaceutical company founded in 2009 in Barcelona (Spain) with a business and expanding presence in Cambridge, Massachusetts (United States). The company's business strategy consists of identifying, clinically developing and marketing drugs to treat rare neurological diseases, using drugs already on the market (repurposing).YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Raúl Insa
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW SOM BIOTECH:
Tweets by SOM Biotech
6 articles about SOM Biotech
-
SOM Biotech announces the in vitro confirmation of three drug candidates for COVID-19 in collaboration with the Ewha Womans University
4/20/2020
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately.
-
SOM Biotech Achieves Relevant Advances in its Pipeline Leveraging on its Proprietary AI-based Drug Discovery Technology SOM[AI]- PRO
1/13/2020
SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases, closes a remarkable year, achieving relevant advances in its drug development pipeline leveraging on its proprietary AI-based drug discovery technology SOMAI-PRO.
-
SOM Biotech Closes a Financing Round of 7M Euros
3/7/2019
SOM Biotech has just closed a financing round of 7 million euros led by a holding company belonging to a European family with a long tradition in the pharmaceutical sector which will give the opportunity to get a facilitated access to pharma network.
-
SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington's Disease Patients
7/17/2018
SOM Biotech has announced the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington's disease.
-
Nippon Chemiphar Co., Ltd. And SOM Biotech To Cooperate On New, Orphan Disease Indications For Bevantolol (Calvan)
10/11/2017
-
SOM Biotech Licenses Its First Product And Expands To The United States
7/25/2017